Drug Safety Fears May Limit Reimporting and Shape R&D
Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2005
Volume 29
Issue 2
Concerns about risky medicines may reduce pressure to expand drug imports while boosting demand for more comparative analyses of therapies.
Articles in this issue
Correcting the Course
Using Extrusion-Spheronization to Develop Controlled-Release Formulations of Azithromycin
Toward a Generic Approach for Stress Testing of Drug Substances and Drug Products
February 2005
Good Work and True: USP Prepares for Convention 2005
Contract Manufacturers Getting Squeezed
In the Spotlight-February 2005
Emerging Analytical Technology: Moving from the Lab to the Line
Drug Safety Fears May Limit Reimporting and Shape R&D
In Defense of USP Singlet Testing
Recent Videos
Related Content
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Article
Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
